Blue California files patent for ergothioneine as support for oxidative stress related conditions
Blue California (Rancho Santa Margarita, CA) has filed a patent for the therapeutic uses of ergothioneine.
Photo © Shutterstock.com/jovan vitanovski
Blue California (Rancho Santa Margarita, CA) has filed a patent for the therapeutic uses of ergothioneine. This follows the firm’s February 2020 patent application reporting the discovery that ergothioneine inhibits the shortening of telomeres associated with oxidative stress. The most recent patent claims ergothioneine mitigates oxidative stress triggering the inflammatory response in chronic conditions associated with heart disease, diabetes, and cancer.
“Blue California has been at the forefront of research and development regarding ergothioneine using our branded ingredient ErgoActive,” stated Priscilla Samuel, PhD, chief science officer at Blue California, in a press release. “We have found through our research that ergothioneine has tremendous potential to combat oxidative stress and health conditions associated with it.”
Ergothioneine is a naturally-occurring amino acid that comes from a number of dietary sources such as mushrooms. Researchers speculate that ergothioneine is important to human health because we produce a highly specific transport protein called OCTN1 for the amino acid. For its branded ingredient ErgoActive, Blue California received no objection for its GRAS notification from the U.S. Food and Drug Administration. Blue California is the exclusive manufacturer and distributor of ErgoActive for Conagen (Bedford, MA), a biotechnology company with a large portfolio of products for the food, nutrition, and pharma markets.
More research is on the way. “Blue California recently invested in both in vitro and in vivo research of ErgoActive,” said Samuel. “We will be studying how ergothioneine supplementation can support various health benefits, including immune health. We also look forward to clinical studies that further test and demonstrate these novel benefits included in our patent application, and in the emerging scientific literature.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
